{
    "nct_id": "NCT02987543",
    "official_title": "A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)",
    "inclusion_criteria": "Inclusion criteria\n\n1. Histologically confirmed diagnosis of prostate cancer.\n2. Documented evidence of metastatic castration resistant prostate cancer (mCRPC).\n3. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC .\n4. Ongoing therapy with LHRH analog or bilateral orchiectomy.\n5. Radiographic progression at study entry while on androgen deprivation therapy (or after bilateral orchiectomy).\n6. Qualifying HRR mutation in tumor tissue.\n\nExclusion criteria\n\n1. Any previous treatment with PARP inhibitor, including olaparib.\n2. Subjects who have any previous treatment with DNA-damaging cytotoxic chemotherapy, except if for non-prostate cancer indication and last dose > 5 years prior to randomization.\n3. Other malignancy (including MDS and MGUS) within the last 5 years except: adequately treated non-melanoma skin cancer or other solid tumors curatively treated with no evidence of disease for ≥5 years.\n4. Subjects with known brain metastases.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}